Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer

NCT00658580 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

361

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Carcinoma, Extensive Disease

Interventions

DRUG: Cisplatin + etoposide
DRUG: Epirubicin + ifosfamide + etoposide

Sponsor

European Lung Cancer Working Party